Developing Novel, First in Class Drug,
Treating and Preventing
Type 2 Diabetes,
Based on a Core-Technology-Platform.
Pipeline (IND in process):
Type 2 Diabetes drug
Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use.
These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. Concenter BioPharma is developing and commercializing the drug which treats and prevents Type 2 Diabetes.
The drug has 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases (and anecdotal human cases).
Members of our PLATFORM act as:
(i) Potent anti-inflammatory agents,
(ii) Strong iron-chelating agents, and
(iii) Anti-biotic agents.
Becoming a global specialty biopharmaceutical company by advancing a pipeline of products that demonstrate vast potential for treating TYPE 2 DIABETES.
Thank you to all the investors which participated in our campaign on the Pipelbiz crowdfunding site (ended 24/09/2020). We reached our goal of raising 4M NIS.
Concenter Biopharma granted approval for Phase 2a Clinical Trial at Sheba Medical Center (Israel).
Zygosid-50 could be the first diabetes drug to restore near-normal cellular sensitivity to insulin, without side effects.
Concenter BioPharma is currently raising funds for conducting this trial.
Concenter BioPharma's co-founder and CSO, Prof. Mottie (Mordechai) Chevion said: “the unique property of our drug candidate - Zygosid-50 - is that it cancels out insulin resistance".
Concenter BioPgharma' Type 2 Diabetes Drug - "Zygosid-50" has been awarded FIRST PLACE at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), December 7th, 2019 in Los Angeles.
Prof. Mottie Chevion, CSO, received the award from Zachary Bloomgarden, MD.
It is a great honor to receive this recognition for our achievements from the global leading researchers, physicians-clinicians and other healthcare professionals in the field!
The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice in pursuit of the theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
Concenter BioPharma to present its Type 2 Diabetes Drug at the -
WORLD CONGRESS INSULIN RESISTANCE DIABETES & CARDIOVASCULAR DISEASE -
December 4-7, Los Angeles. Our session-presentation is December 6th, 18:45.
Looking forward to seeing you there!
Come see us and hear our presentation at the 19TH ANNUAL BIOTECH IN EUROPE FORUM FOR GLOBAL PARTNERING & INVESTMENT (25TH-26TH SEPTEMBER 2019) - CONGRESS CENTER BASEL, SWITZERLAND
We have been chosen as 1 in 20 companies (Globally) to present - "Rising Stars - Global Seed Session"
The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies.
We are proud to announce that Prof. Dr. med. Dr. h.c. Peter Paul Nawroth has joined our Scientific Advisory Board.
Among his many achievements, Prof. Nawroth is the awardee of the 2018 Camillo Golgi Prize - a
Prize for outstanding contributions in the field of the histopathology, pathogenesis, prevention and treatment of the complications of diabetes mellitus. Prof. Nawroth was awarded the prize for his work on "Diabetic complications: an alternative view on diabetes"
Come meet us and hear our presentation at the 3rd World Congress on Clinical Trials in Diabetes (WCTD2018), which will take place 3-4 December 2018 in Vienna, Austria.
WCTD2018 follows the success of the first two Congresses, both held in Berlin, and will continue to address the multitude of complex issues associated with clinical trials in diabetes.
TiE Inflect 2018 announces
CONCENTER BIOPHARMA as a
2018 TiE50 Finalist.
CONCENTER BIOPHARMA is excited to announce that it has been selected as a "2018 TiE50 Finalist" for the prestigious TiE50 Awards Program recognizing the world's most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world's largest conference for tech entrepreneurs.
"We are honored and excited to have been chosen as a finalist out of over 7000 companies from around the world! Our plan is to begin clinical trials for our Type 2 Diabetes drug in the coming months..." said Dror Chevion, Co-Founder and CEO of the company.
"TiE50 has become a global brand that attracts thousands of tech startups worldwide. This year, we screened more than 7400 companies from 28 countries and selected the best-of-breed as our "2018 TiE50 Finalists". These companies are finalists in the ultimate runoff for the 50 winners. Our program has gained notoriety over the past decade as a competition run with the highest level of integrity and vigorous screening and judging by domain experts". - Kamal Anand, TiE50 Program Chair
"As a 26-year not-for-profit dedicated to fostering entrepreneurship and with a global footprint of half million entrepreneurs, enterprise executives, and investment professionals, we pride in the fact that we are one of very few competitions without any pay-to-play incentives" Ram K. Reddy, President, TiE Silicon Valley.
We are proud to announce that Prof. Ralph DeFronzo has joined our Scientific Advisory Board.
Prof. DeFronzo, is directly responsible for many of the advances achieved in diabetes over the last 50 years. He was a leader in developing the concept of insulin resistance, the defining characteristic of Type 2 diabetes, resulting in novel ideas about the development and progression of diabetes.
DeFronzo led the U.S. development of metformin, the first-line medication for treatment of diabetes, and ushered it through FDA approval in 1995. More recently, he discovered a new approach to diabetes treatment that targets glucose reabsorption in the kidneys. This work led to the development and approval of other widely used drugs, including dapagliflozin, empagliflozin and canagliflozin.
DeFronzo is the author of 750 publications dating back to 1967. He currently serves as professor of medicine and chief of diabetes in the Long School of Medicine at University of Texas Health San Antonio, where he has been on faculty since 1988.
The 6th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) to be held in Tel Aviv, Israel, February 21-22, 2018.
Come see our poster and talk to us about our upcoming submission of our IND for Treating Type 2 Diabetes.
Looking forward to seeing you there.
Come meet us and hear our presentation at the 2nd World Congress on Clinical Trials in Diabetes (WCTD2017), which will take place 27-28 November 2017 in Berlin, Germany.
WCTD2017 follows the success of the 1st inaugural Congress held in Berlin in November 2016 and will continue to address the multitude of complex issues associated with clinical trials in diabetes.
GREAT NEWS (29.10.2017)!
We have been chosen as 1 out of 5 Israeli companies that will continue to the Semi-Final Competition in China - December.
We are among the 20 chosen companies from Israel (in all fields)...Come meet us - Israeli session of IPIEC Global Start-Up Competition.
The event will take place on 29.10.2017 at the LAGO event center - 6, HaMea VeEsrim St, Rishon Leziyon.
You are invited to meet some of Israel's most promising start-ups as well as representatives from China, who came especially to the event.
20 Israelis companies will attend, and will pitch on stage in front of the judge panel composed of Israelis and Chinese.
5 companies will proceed to the next stage that will take place in china.